|
|
||||||||
J Thorac Cardiovasc Surg 1997;113:901-909
© 1997 Mosby, Inc.
SURGERY FOR ACQUIRED HEART DISEASE |
Received for publication August 6, 1996 revisions requested Oct. 4, 1996; revisions received Nov. 1, 1996 accepted for publication Nov. 8, 1996. Address for reprints: Ruggero De Paulis, MD, Cattedra di Cardiochirurgia, Università di Roma, Tor Vergata, European Hospital, via Portuense 700, 00149 Rome, Italy.
Abstract
Objective: To assess the extent and pattern of regression of left ventricular hypertrophy after valve replacement for aortic stenosis, we studied 26 patients receiving either 19 or 21 mm CarboMedics valves (group I, 13 patients) or either 23 or 25 mm CarboMedics valves (group II, 13 patients). The studies were done before the operation and after 3 years, and results were compared with those of 10 control patients.Methods: Left ventricular end-diastolic and end-systolic diameters and volumes, ejection fraction and fractional shortening, and interventricular septum and posterior wall thickness were measured. The ratio between interventricular septum and posterior wall thickness, the ratio between left ventricular wall thickness and left ventricular chamber radius, and the left ventricular mass were then calculated.Results: At follow-up there was a significant reduction in the left ventricular mass, interventricular septum, and posterior wall thickness for both patient groups (p < 0.01). However, only the posterior wall thickness reached normal values; the interventricular septum and the left ventricular mass indices were still significantly greater than in the control group (p < 0.01). Because of the incomplete regression of interventricular septal hypertrophy, the ratio between interventricular septum and posterior wall thickness was similar between both patient groups but it was significantly higher than in control subjects (p < 0.01). The ratio between wall thickness and chamber radius did not decrease significantly in group II patients, in whom it remained above the control values.Conclusion: Having a bileaflet aortic prosthesis of one size larger did not seem to significantly influence the pattern and the extent of regression of left ventricular hypertrophy after an intermediate period of follow-up.
Residual postoperative gradients are often present after aortic valve replacement with a prosthetic valve. These gradients are progressively higher as the size of the prosthetic valve decreases. Therefore small prosthetic valves might become relatively stenotic, especially when implanted in patients with a large body surface area (BSA). The presence of a significant postoperative gradient has been thought to be responsible for adverse long-term mortality and morbidity. In fact, the residual postoperative gradient might influence the extent of regression of left ventricular hypertrophy that, in turn, is responsible for a higher incidence of arrhythmias and impaired ventricular function. In this study we wanted to analyze the pattern and extent of regression of hypertrophy in a group of patients receiving small CarboMedics aortic prosthetic valves (CarboMedics, Inc., Austin, Tex.) and compare the results with those of another group receiving larger valves and with a control group.
Patients and methods
Patient population.
Twenty-six ambulatory patients who had prior aortic valve replacement for severe aortic stenosis were considered. Patients selected for the study were those who had the preoperative echocardiographic evaluation at our institution, who did not have other associated valvular or coronary diseases, and who had no history of systemic hypertension. Three groups of patients were considered. The first group (group I) comprised 13 patients receiving either a 19 mm (n = 5) or a 21 mm CarboMedics (n = 8) prosthetic valve. The second group (group II) comprised 13 patients who received either a 23 mm (n = 10) or a 25 mm (n = 3) CarboMedics prosthetic valve. The third group of 10 healthy subjects, with no heart valve disease on routine diagnostic echocardiography and no history of systemic hypertension, served as a control.
All patients were evaluated before the operation and after a mean period of 30 ± 7 months for group I and of 32 ± 5 months for group II (p = not significant). Medical ethics committee approval and informed patient consent for participation in the study were obtained in all cases.
Patient characteristics are shown in
Table I. A higher number of female patients was present in the smaller valve group, consistent with the fact that women have a smaller BSA and smaller aortic root. Although the BSA was smaller in the patients in group I, it was not significantly different from that of the other two groups. As a result, when the orifice areas of the prosthesis (effective orifice area as measured in vitro and obtained from the manufacturer) were indexed for the BSA to obtain the effective area index, a significant difference from patients in group II was found. Therefore, in patients in group I a significantly higher mismatch between prosthetic valve area and BSA was found (effective area index = 0.7 cm2/m2,
Table I). Although the majority of patients had pure aortic stenosis, a moderate degree of regurgitant volume was present in one patient in group I and in two patients in group II.
|
Statistical analysis.
One-factor analysis of variance was used to compare echocardiographic parameters among patient groups at each observation point. When significant differences were detected, pairwise comparisons were made by the Scheffè F test. One-way analysis of variance for repeated measures was used to compare echocardiographic parameters at the time of operation and at follow-up. Comparisons of the remaining continuous or discrete variables between the two groups were performed with an unpaired Student's t test or a
2 test, respectively (SPSS for Windows Software, SPSS, Inc., Chicago, Ill.). Data are expressed as mean ± 1 standard deviation, unless otherwise indicated; p values < 0.05 were considered significant.
Results
New York Heart Association (NYHA) functional class improved in all patients. At each follow-up period the majority of patients (21/26, 81%) were in NYHA class I, and the remaining were in class II (19%).
Echocardiographic measurements of left ventricular diameters and volumes and assessment of left ventricular function at follow-up for groups I and II and those for the control group are shown in
Table II.
|
Preoperatively, the left ventricular mass index was significantly greater in both groups of patients than in the control subjects (Fig. 1,
Table III). Although at the postoperative study both patient groups exhibited a significant decrease in left ventricular mass, it remained significantly greater than in the control group.
|
|
|
|
|
Preoperatively, the ratio of left ventricular wall thickness to radius (Th/r) was significantly higher in both groups of patients than in the control group. In group I it decreased over time, and at the follow-up it was within the control values and significantly different from the preoperative values (Fig. 4,
Table III). In group II the postoperative ratio of left ventricular wall thickness to radius (Th/r) did not decrease significantly, and therefore at the postoperative study it was still significantly higher than in the control group. (This result was due to an earlier and complete normalization of ventricular volumes, which were slightly larger than in group I, compared with the slower and incomplete regression of the septal thickness.)
For patients in group I who had been evaluated for another study protocol, a shorter follow-up (10.4 ± 6.2 months) was also available, and no significant differences for all parameters considered could be detected between the two follow-up periods.
Discussion
The development of concentric hypertrophy in patients with aortic stenosis or systemic hypertension is an appropriate adaptation of the left ventricular muscle to the increase in the intracavitary pressure,
2 which allows it to maintain a normal relation between systolic wall stress and ejection fraction. However, in hypertensive patients the presence of concentric hypertrophy is associated with increased morbidity and mortality.
3,4 Similarly, in patients with aortic stenosis, it has been found associated with increased postoperative mortality after aortic valve replacement.
5 These findings were related to several mechanisms, including a suboptimal myocardial protection of the hypertrophied heart, an abnormality in coronary flow reserve, and an exacerbation of diastolic dysfunction. Besides the increased perioperative mortality and morbidity associated with marked concentric ventricular hypertrophy, it is possible that the lack of regression of left ventricular hypertrophy after aortic valve replacement might negatively influence the long-term prognosis of this subset of patients. In the majority of cases, implantation of an aortic valve prosthesis corrects the abnormal hemodynamic burden and causes a regression of the left ventricular hypertrophy. However, the use of small aortic valve prostheses and therefore the possibility of a patient-prosthesis mismatch raises the concern that the regression of hypertrophy and the remodeling of the left ventricular geometry might not take place.
This assumption is often based on the evidence that residual postoperative gradients are often found after aortic valve replacement with small prosthetic valves. These gradients are more marked with the use of porcine valves or with the first generation of mechanical valves. In the late seventies, several authors recommended that 19 or 21 mm porcine valves
6,7 not be used in adults because they could cause severe transprosthetic gradients, especially during exercise.
8 Many different anulus-enlarging procedures
9,10 have been recommended to allow the implantation of larger prostheses. The use of the tilting disc mechanical valve greatly decreased the rest and exercise gradients, so that the long-term survival and clinical status reportedly has been unaffected by the use of small prosthesis sizes.
11 However, some authors
12 still found unsatisfactory the hemodynamic performances of 19 mm tilting disc valves.
The advent of bileaflet valves with their improved hemodynamic performances has somehow overcome the disadvantages of using small valves. Most studies evaluating the St. Jude Medical mechanical valve (St. Jude Medical, Inc., St. Paul, Minn.) reported catheterization mean gradients varying from 7 to 14 mm Hg for the 19 mm valve,
13,14 and similar values were also found on the catheterization-derived gradients for the CarboMedics valve.
15 However, most of the time the Doppler-derived gradients are used to evaluate and to compare different valve prostheses. We recently found postoperative Doppler gradients for small CarboMedics valves in the range of 35 mm Hg after exercise.
16 Similarly, Doppler-derived gradients for the 21 mm St. Jude Medical and CarboMedics valves in the range of 7 mm Hg at rest and 24 mm Hg after dobutamine stress echocardiography have been reported.
17 Although a good correlation between catheter-derived and Doppler-derived gradients has been reported,
18,19 it is widely known that Doppler-defined gradients in bileaflet valves are often overestimated by comparison with catheter-derived gradients.
20 This is due to the presence of high localized gradients and to the phenomenon of pressure recovery distal to the aortic prosthesis. Another source of error in the Doppler-derived gradients might also derive from their dependence on the opening angle of the valve. In case of valve malfunction with restricted leaflet movements, the increase of Doppler-derived gradients has been found to be considerably smaller than the increase in catheter-derived gradients.
21 Considering that a prosthesis evaluation based solely on the measurement of residual Doppler-derived gradient might not be satisfactory, we thought that a more accurate evaluation of small aortic prostheses should be based on the close observation of the extent, pattern, and rate of regression of left ventricular hypertrophy. Monrad and associates
22 followed the regression of hypertrophy at an intermediate (1.6 years) and a late (8 years) period after aortic valve replacement with different valve prostheses. They noted that the regression of hypertrophy was conspicuous after surgery by the time of the intermediate study but continued at a slower rate thereafter. They concluded that the improvements occurring at a slight but constant afterload excess for the presence of the valve prosthesis indicates that the hypertrophied myocardium is operating at a reduced level. However, even late after aortic valve replacement, a moderate degree of hypertrophy was still present. Our study demonstrated that, within certain limits, there is no difference in the extent and pattern of regression of left ventricular hypertrophy in patients with different mismatches between valve prosthesis and BSA. Although after 3 years of follow-up a normalization of the myocardial mass was not obtained, a significant regression of left ventricular hypertrophy was present in all patients. The lack of normalization of myocardial mass was mainly due to the incomplete regression of the hypertrophy of the interventricular septum. It is known that in the interventricular septum there is a higher fibrous reaction and the fibrous content takes longer to decrease significantly.
23 Nonetheless, the same results were found for patients with effective area indexes varying from 0.7 to 1 cm2/m2. Therefore it is possible that for the bileaflet valve the minimum requirement of 0.9 cm2/m2 previously suggested and based on reports
24,25 evaluating different types of bioprostheses or first-generation mechanical valves could be safely lowered.
Grouping together all valves and correlating the effective area index with the interventricular septum thickness and with the left ventricular mass, we were unable to find a point at which effective area index of the prosthesis was too small to negatively influence the regression of left ventricular hypertrophy (r = 0.42, p = 0.03). Therefore this study shows that even patients with an effective area index as low as 0.7 cm2/m2 were able to obtain a satisfactory regression of left ventricular hypertrophy. Although an effective orifice area between 0.6 and 0.75 cm2/m2 is considered a severe aortic stenosis for a natural valve, it might still significantly decrease the left ventricular hypertrophy when it is related to a bileaflet prosthetic valve with optimized flow hemodynamics.
Although a larger valve prosthesis yields better hemodynamic performances, from a clinical point of view it is difficult to demonstrate a significantly worse result in the majority of patients with small valve prostheses. In a group of patients with small St. Jude Medical valves after 12 years of follow-up, Kratz and associates
26 reported that having a small valve was not predictive of persistent congestive heart failure or late death. A small increase in the risk of sudden death was found only in patients with a BSA of more than 1.9 m2 receiving a 19 mm prosthesis. Similarly, in a large group of patients followed up for 18 years, who received different kinds of valves smaller than 21 mm, He and associates
27 found that a mismatch between BSA and prosthesis size is a negative determinant for long-term survival only in patients with concomitant coronary artery bypass grafting. Previously, Foster and coworkers,
11 evaluating 17 and 19 mm Björk-Shiley valve prostheses, found that 93% of the patients with resting gradients higher than 30 mm Hg were in NYHA class I and concluded that resting hemodynamic studies have a limited predictive value for long-term prognosis. It is therefore evident that information on the extent of regression of left ventricular hypertrophy might be more valuable for the surgeon dealing with a small aortic anulus.
In a recent review article, Barner and colleagues
28 stated that after a 6-month observation period patients with small mechanical valves had lower reduction in left ventricular mass index, decreased exercise tolerance, and higher functional class than patients with larger valves. In particular, they found that valve size was an independent determinant (although with a weak correlation, r = 0.26) of functional class. The difference from our study could be due either to the different follow-up period or to a different surgical timing.
A difference in the regression of left ventricular hypertrophy after aortic valve replacement for aortic stenosis has also been noted in patients with preoperative depressed ventricular function.
29 Although our group II patients had slightly enlarged ventricles, their ventricular function was normal and we could not include this variable in the analysis. Finally, Sim and associates
30 analyzed the influence of prosthesis size on the change in left ventricular mass and concluded that 19 mm valves might not provide comparable reduction in left ventricular mass after aortic valve replacement. However, in their study, although the magnitude of reduction in left ventricular mass was greater in patients with valve size 21 mm or larger, it did not reach statistical significance. More important, all groups approached similar values in the postoperative measurements of left ventricular mass index. These findings seem to indicate that, although patients with different valve sizes might have a different rate of reduction in left ventricular hypertrophy, all patients obtain a regression of left ventricular hypertrophy to a certain point, after which it continues at a much slower rate.
22 Although the numbers might be too small for meaningful conclusions, also when we compared patients with 19 mm valves (n = 5) and those with 21 mm valves (n = 8) (which combined in group I), we did not find any significant difference in all parameters considered.
The lack of substantial differences observed between our two groups of patients, even in the extent and pattern of regression of ventricular hypertrophy, testifies to the overall good performances of small bileaflet valves and confirms that in the presence of a postoperative residual gradient a longer time is probably needed for a more complete regression of left ventricular hypertrophy.
Conclusions
It seems intuitive that a more complete relief of obstruction is obtained with the implantation of a larger valve prosthesis. Therefore, especially in the small aortic root, surgeons usually attempt to implant the largest possible valve. However, this study suggests that in most patients the possibility and the ability to implant a prosthesis one size larger might not be justified by a significant difference, not only in the clinical status but also in the pattern and extent of regression of ventricular hypertrophy. Therefore the risk associated with an anulus-enlarging procedure or with the use of improved versions of currently available bileaflet valves, whose results are still uninvestigated, should be weighed against the trivial differences in the postoperative clinical status and the extent of regression of left ventricular hypertrophy. The new Hemodynamic Plus St. Jude Medical valve (St. Jude Medical HP) that has the same orifice as the next larger standard valve and the supraanular version of the CarboMedics valve (Top-hat) should demonstrate the same valve-related complications as the standard version before their use will be widespread.
Given the fact that in most cases the size of the prosthesis for aortic valve replacement is correlated to the body size of the patient, there are very few cases in which the mismatch between valve prosthesis and BSA seems to be significant to the point that a prosthesis of one size larger might influence the regression of left ventricular hypertrophy.
Study limitations
A limitation of this study is that the rate of regression at a longer follow-up was not analyzed. It is possible that in patients with larger valve prostheses the regression of hypertrophy will continue many years after the operation, as demonstrated by Monrad,
22 Krayenbuehl,
23 and their associates, whereas in the smaller valve group it might not take place. A longer follow-up period is required to unveil this aspect. Furthermore, we did not analyze the differences in the rate of regression between the two group within the first year. However, if these differences did exist, they would require monthly echocardiographic studies within the year and they would probably not have clinical relevance. Finally, the small group of patients considered might account for a less accurate statistical validation of the results. However, the patient selection needed to be very accurate, because the patients were categorized not only according to valve type and size, but also according to the absence of significant valve regurgitation, the absence of hypertension, and other cardiac abnormalities or procedures. Nonetheless, the evaluation of this small group of patients allowed us to conclude that bileaflet valves might offer good hemodynamic performance to the point that in a large number of cases a small difference in prosthesis size not only is not clinically relevant, but might not significantly influence the regression of left ventricular hypertrophy.
Acknowledgments
We thank A. Parma, MD, MSc, for his assistance in the statistical analysis of our data.
Footnotes
From the Cardiac Surgery Department, Tor Vergata University of Rome, Rome, Italy. ![]()
References
This article has been cited by other articles:
![]() |
M. Doss, J. P. Wood, S. Martens, G. Wimmer-Greinecker, and A. Moritz Do Pulmonary Autografts Provide Better Outcomes Than Mechanical Valves? A Prospective Randomized Trial Ann. Thorac. Surg., December 1, 2005; 80(6): 2194 - 2198. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Imanaka, O. Kohmoto, S. Nishimura, Y. Yokote, and S. Kyo Impact of postoperative blood pressure control on regression of left ventricular mass following valve replacement for aortic stenosis Eur. J. Cardiothorac. Surg., June 1, 2005; 27(6): 994 - 999. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Penta de Peppo, J. Zeitani, P. Nardi, G. Iaci, P. Polisca, R. De Paulis, and L. Chiariello Small "Functional" Size after Mechanical Aortic Valve Replacement: No Risk in Young to Middle-Age Patients Ann. Thorac. Surg., June 1, 2005; 79(6): 1915 - 1920. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Tasca, F. Brunelli, M. Cirillo, A. Amaducci, Z. Mhagna, G. Troise, and E. Quaini Mass regression in aortic stenosis after valve replacement with small size pericardial bioprosthesis Ann. Thorac. Surg., October 1, 2003; 76(4): 1107 - 1113. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Khan and A. Trento Is it better on top? The triumph of supra-annular valves J. Thorac. Cardiovasc. Surg., March 1, 2003; 125(90030): S12 - 13. [Full Text] [PDF] |
||||
![]() |
G. Dellgren, C. M. Feindel, J. Bos, J. Ivanov, and T. E. David Aortic valve replacement with the Toronto SPV: long-term clinical and hemodynamic results Eur. J. Cardiothorac. Surg., April 1, 2002; 21(4): 698 - 702. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Khan and A. Trento Is it better on top? The triumph of supra-annular valves J. Thorac. Cardiovasc. Surg., October 1, 2001; 122(4): 645 - 646. [Full Text] [PDF] |
||||
![]() |
I. Knez, R. Rienmuller, R. Maier, P. Rehak, B. Schrottner, H. Machler, M. Anelli-Monti, and B. Rigler Left ventricular architecture after valve replacement due to critical aortic stenosis: an approach to dis-/qualify the myth of valve prosthesis-patient mismatch? Eur. J. Cardiothorac. Surg., June 1, 2001; 19(6): 797 - 805. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. S. Khan, R. J. Siegel, M. A. DeRobertis, C. E. Blanche, R. M. Kass, W. Cheng, G. P. Fontana, and A. Trento Regression of hypertrophy after Carpentier-Edwards pericardial aortic valve replacement Ann. Thorac. Surg., February 1, 2000; 69(2): 531 - 535. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. B. Izzat, I. Kadir, B. Reeves, P. Wilde, A. J. Bryan, and G. D. Angelini Patient-prosthesis mismatch is negligible with modern small-size aortic valve prostheses Ann. Thorac. Surg., November 1, 1999; 68(5): 1657 - 1660. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Rao, G. T. Christakis, J. Sever, S. E. Fremes, G. Bhatnagar, G. Cohen, M. A. Borger, L. Abouzahr, and B. S. Goldman A NOVEL COMPARISON OF STENTLESS VERSUS STENTED VALVES IN THE SMALL AORTIC ROOT J. Thorac. Cardiovasc. Surg., March 1, 1999; 117(3): 431 - 438. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. D. Paulis, MD, L. Sommariva, MD, L. Colagrande, MD, G. M. De Matteis, MD, S. Fratini, MD, F. Tomai, MD, C. Bassano, MD, A. P. de Peppo, MD, and L. Chiariello, MD REGRESSION OF LEFT VENTRICULAR HYPERTROPHY AFTER AORTIC VALVE REPLACEMENT FOR AORTIC STENOSIS WITH DIFFERENT VALVE SUBSTITUTES J. Thorac. Cardiovasc. Surg., October 1, 1998; 116(4): 590 - 598. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. E. David, R. Puschmann, J. Ivanov, J. Bos, S. Armstrong, C. M. Feindel, and H. E. Scully Aortic valve replacement with stentless and stented porcine valves: a case-match study J. Thorac. Cardiovasc. Surg., August 1, 1998; 116(2): 236 - 240. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |